CHANGES IN CENTRAL CHOROIDAL THICKNESS AFTER TREATMENT OF DIABETIC MACULAR EDEMA WITH INTRAVITREAL BEVACIZUMAB CORRELATION WITH CENTRAL MACULAR THICKNESS AND BEST-CORRECTED VISUAL ACUITY.

Abstract

PURPOSE:

To assess the effect of intravitreal injection of bevacizumab on central choroidal thickness (CCT) and its relationship with central macular thickness (CMT) and best-corrected visual acuity (BCVA) changes in eyes with center-involving diabetic macular edema.

METHODS:

This prospective interventional case series included 20 eyes of 20 patients with center-involving diabetic macular edema naive to treatment. The BCVA assessment, complete eye examination, enhanced depth optical coherence tomography, and fluorescein angiography were performed at baseline followed by 3 monthly intravitreal injection of bevacizumab. The treated eyes underwent BCVA evaluation and enhanced depth optical coherence tomography at Months 1, 2, 3, and 6 after the first injection. Change of the CCT was the primary outcome measure. Secondary outcome measures included BCVA and CMT changes and their relationship with CCT changes.

RESULTS:

Mean age of patients was 63.1 ± 8.0 (range, 52-75) years. Mean baseline CCT was 265 ± 79 μm, which reduced to 251 ± 81 μm and 232 ± 82 μm at Months 3 and 6, respectively (P < 0.001). Corresponding values for CMT were 470 ± 107 μm, 392 ± 104 μm, and 324 ± 122 μm, respectively (P < 0.001). The BCVA improved from 20/60 at baseline to 20/50 at Month 3 and 20/40 at Month 6 (P = 0.007). Each 1 μm decrease in CCT was associated with 2.74 μm reduction in CMT and 0.1 Early Treatment Diabetic Retinopathy Study letter score improvement in BCVA (P < 0.001 and P = 0.001, respectively).

CONCLUSION:

After treatment of diabetic macular edema with intravitreal injection of bevacizumab, CCT decreased and this reduction significantly correlated with CMT reduction and vision improvement.

• Authors: Ramin Nourinia, Hamid Ahmadieh, Elnaz Nekoei, Parviz Malekifar, Zahra Tofighi
• Journal: Retina (Philadelphia, Pa.) (Retina) Vol. 38 Issue 5 Pg. 970-975 (May 2018) ISSN: 1539-2864 [Electronic] United States
• PMID: 28426622 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Bevacizumab

Topics

• Adult
• Aged
• Angiogenesis Inhibitors (administration & dosage)
• Bevacizumab (administration & dosage)
• Choroid (pathology)
• Diabetic Retinopathy (drug therapy, pathology, physiopathology)
• Female
• Humans
• Intravitreal Injections
• Macula Lutea (pathology)
• Macular Edema (drug therapy, pathology, physiopathology)
• Male
• Middle Aged
• Prospective Studies
• Tomography, Optical Coherence
• Visual Acuity (physiology)